Improving stroke treatment with a modified therapeutic molecule
A research team from the Institut national de la recherche scientifique (INRS) has improved the protective effect of a molecule against ischemic stroke, which is caused by an interruption of blood flow to the brain.
Every year in Quebec, about 20,000 people have a stroke. Also known as a “cerebral infarction,” this sudden neurological deficit can lead to psychological and physical after-effects. These effects result from an increase in glutamate in the brain, which destroys neurons. “Glutamate is an essential neurotransmitter for neuronal communication, learning and memory processes, yet above a certain concentration, it becomes toxic to neuronal cells,” explains Ahlem Zaghmi, a newly graduated INRS doctoral student under the supervision of Professor Marc A. Gauthier.
The research team aimed at developing an effective treatment that would compensate for the increase in glutamate, in collaboration with a Spanish team. What makes its approach unique? It works on the periphery.
“Unlike other drugs, our molecule does not need to cross the blood-brain barrier to achieve its therapeutic effect. It represents one fewer obstacle, since it could be injected intravenously,” explains Ahlem Zaghmi.
The modified molecule, glutamate-oxaloacetate transaminase (GOT), is already known for its therapeutic effects. This enzyme breaks down the glutamate circulating in the bloodstream which creates a kind of siphon effect. “By decreasing concentrations of this neurotransmitter in the blood, excess glutamate in the brain will move out to compensate for the loss. This “siphons” the glutamate out of the brain,” she says.
A single dose of the molecule typically lasts three hours in rats. Due to the modification made by the research team, the treatment is now effective for six days. “Adding a polymer, polyethylene glycol, on the surface of the GOT enzyme increases its circulation time in the blood. The polymer will, among other things, protect the molecule from the immune system,” says Professor Gauthier, a specialist in bioorganic chemistry and biomaterials.
This has the advantage of maintaining the siphon effect over a period of time that exceeds the duration of the glutamate peak caused by the stroke in the brain, while reducing the number of doses given and the risk of side effects,” adds Ahlem Zaghmi.
The research team now intends to observe the longer-term effect of the molecule and explore applications to other neuronal diseases. Since glutamate toxicity is also associated with head trauma, Parkinson’s and Alzheimer’s disease, the research group could, among other things, test whether the modified molecule accelerates healing or, if so, slows the development of the disease.
This article is has been republished with the permission of l’Institut national de la recherche scientifique.
Bilingual infants prefer baby talk
Infants prefer baby talk in any language, but particularly when it’s in a language they’re hearing at home.